Partition-variant desferrithiocin analogues: Organ targeting and increased iron clearance

Journal of Medicinal Chemistry

Volumn 48, Issue 3, 2005, Pages 821-831

  Bergeron, Raymond J ^a   Wiegand, Jan ^a   McManis, James S ^a   Weimar, William R ^a,c   Park, Jeong Hyun ^a   Eiler McManis, Eileen ^a   Bergeron, Jennifer ^a   Brittenham, Gary M ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b Columbia Univ Coll Phys Surgs ^*  (United States)

^c SOUTHERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,3 DIHYDROXYPHENYL) 4,5 DIHYDRO 4 METHYL 4 THIAZOLECARBOXYLIC ACID; 4,5 DIHYDRO 2 (2 HYDROXY 3 METHOXYPHENYL) 4 METHYL 4 THIAZOLECARBOXYLIC ACID; CARBOXYLIC ACID DERIVATIVE; DEFERRIFERRITHIOCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHELATION; CONTROLLED STUDY; GENE TARGETING; HEART; HYDROXYLATION; LIGAND BINDING; LIPOPHILICITY; LIVER; LIVER MICROSOME; METHYLATION; NONHUMAN; OXIDATION; PANCREAS;

ANIMALS; ANTIOXIDANTS; ASCORBIC ACID; CATECHOLS; CEBUS; DIHYDROPYRIDINES; FREE RADICAL SCAVENGERS; HUMANS; IRON; IRON CHELATING AGENTS; LIVER; MALE; MYOCARDIUM; OXIDATION-REDUCTION; PANCREAS; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; TISSUE DISTRIBUTION;

EID: 13444249534     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049306x     Document Type: Article

References (70)

1. These results were presented in part at the "Medicinal Inorganic Chemistry" symposium held during the 226th National Meeting of the American Chemical Society, New York, New York, September 11, 2003.
2. Raymond, K. N.; Carrano, C. J. Coordination Chemistry and Microbial Iron Transport. Acc. Chem. Res. 1979, 12, 183-190.
3. Byers, B. R.; Arceneaux, J. E. Microbial Iron Transport: Iron Acquisition by Pathogenic Microorganisms. Met. Ions Biol. Syst. 1998, 35, 37-66.
4. Bergeron, R. J. Iron: A Controlling Nutrient in Proliferative Processes. Trends Biochem. Sci. 1986, 11, 133-136.
5. Theil, E. C.; Huynh, B. H. Ferritin Mineralization: Ferroxidation and Beyond. J. Inorg. Biochem. 1997, 67, 30.
6. Ponka, P.; Beaumont, C.; Richardson, D. R. Function and Regulation of Transferrin and Ferritin. Semin. Hematol. 1998, 35, 35-54.
7. Brittenham, G. M. Disorders of Iron Metabolism: Iron Deficiency and Overload. In Hematology: Basic Principles and Practice; 3rd ed.; Hoffman, R., Benz, E. J., Shattil, S. J., Furie, B., Cohen, H. J.; et al., Eds.; Churchill Livingstone: New York, 2000; pp 397-428.
8. Olivieri, N. F.; Brittenham, G. M. Iron-Chelating Therapy and the Treatment of Thalassemia. Blood 1997, 89, 739-761.
9. Vichinsky, E. P. Current Issues with Blood Transfusions in Sickle Cell Disease. Semin. Hematol. 2001, 38, 14-22.
10. Kersten, M. J.; Lange, R.; Smeets, M. E.; Vreugdenhil, G.; Roozendaal, K. J.; Lameijer, W.; Goudsmit, R. Long-Term Treatment of Transfusional Iron Overload with the Oral Iron Chelator Deferiprone (L1): A Dutch Multicenter Trial. Ann. Hematol. 1988, 73, 247-252.
11. Conrad, M. E.; Umbreit, J. N.; Moore, E. G. Iron Absorption and Transport. Am. J. Med. Sci. 1999, 318, 213-229.
12. Lieu, P. T.; Heiskala, M.; Peterson, P. A.; Yang, Y. The Roles of Iron in Health and Disease. Mol. Aspects Med. 2001, 22, 1-87.
13. Angelucci, E.; Brittenham, G. M.; McLaren, C. E.; Ripalti, M.; Baronciani, D.; Giardini, C.; Galimberti, M.; Polchi, P.; Lucarelli, G. Hepatic Iron Concentration and Total Body Iron Stores in Thalassemia Major. N. Engl. J. Med. 2000, 343, 327-331.
14. Bonkovsky, H. L.; Lambrecht, R. W. Iron-Induced Liver Injury. Clin. Liver Dis. 2000, 4, 409-429, vi-vii.
15. Pietrangelo, A. Mechanism of Iron Toxicity. Adv. Exp. Med. Biol. 2002, 509, 19-43.
16. Carlo, H.; Holl, R. W.; Debatin, K. M.; Kohne, E. Insulin Sensitivity and β-Cell Secretion in Thalassaemia Major with Secondary Haemochromatosis: Assessment by Oral Glucose Tolerance Test. Eur. J. Pediatr. 2003, 162, 139-146.
17. Wojcik, J. P.; Speechley, M. R.; Kertesz, A. E.; Chakrabarti, S.; Adams, P. C. Natural History of C282Y Homozygotes for Hemochromatosis. Can. J. Gastroenterol. 2002, 16, 297-302.
18. Brittenham, G. M.; Griffith, P. M.; Nienhuis, A. W.; McLaren, C. E.; Young, N. S.; Tucker, E. E.; Allen, C. J.; Farrell, D. E.; Harris, J. W. Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major. N. Engl. J. Med. 1994, 331, 567-573.
19. Zurlo, M. G.; De Stefano, P.; Borgna-Pignatti, C.; Di Palma, A.; Piga, A.; Melevendi, C.; Di Gregorio, F.; Burattini, M. G.; Terzoli, S. Survival and Causes of Death in Thalassaemia Major. Lancet 1989, 2, 27-30.
20. Chua, A. C. G.; Olynyk, J. K.; Leedman, P. J.; Trinder, D. Nontransferrin-Bound Iron Uptake by Hepatocytes Is Increased in the Hfe Knockout Mouse Model of Hereditary Hemochromatosis. Blood 2004, 104, 1519-1525.
21. 2+ Channels Provide a Major Pathway for Iron Entry into Cardiomyocytes in Iron-Overload Cardiomyopathy. Nat. Med. 2003, 9, 1187-1194.
22. Graf, E.; Mahoney, J. R.; Bryant, R. G.; Eaton, J. W. Iron-Catalyzed Hydroxyl Radical Formation. Stringent Requirement for Free Iron Coordination Site. J. Biol. Chem. 1984, 259, 3620-3624.
23. Halliwell, B. Free Radicals and Antioxidants: A Personal View. Nutr. Rev. 1994, 52, 253-265.
24. Halliwell, B. Iron, Oxidative Damage, and Chelating Agents. In The Development of Iron Chelators for Clinical Use; Bergeron, R. J., Brittenham, G. M., Eds.; CRC: Boca Raton, FL, 1994; pp 33-56.
25. Koppenol, W. Kinetics and Mechanism of the Fenton Reaction: Implications for Iron Toxicity. In Iron Chelators: New Development Strategies; Badman, D. G., Bergeron, R. J., Brittenham, G. M., Eds.; Saratoga: Ponte Vedra Beach, FL, 2000; pp 3-10.
26. Babbs, C. F. Oxygen Radicals in Ulcerative Colitis. Free Radical Biol. Med. 1992, 13, 169-181.
27. Hazen, S. L.; d'Avignon, A.; Anderson, M. M.; Hsu, F. F.; Heinecke, J. W. Human Neutrophils Employ the Myeloperoxidase-Hydrogen Peroxide-Chloride System to Oxidize α-Amino Acids to a Family of Reactive Aldehydes. Mechanistic Studies Identifying Labile Intermediates along the Reaction Pathway. J. Biol. Chem. 1998, 273, 4997-5005.
28. Samuni, A. M.; Afeworki, M.; Stein, W.; Yordanov, A. T.; DeGraff, W.; Krishna, M. C.; Mitchell, J. B.; Brechbiel, M. W. Multifunctional Antioxidant Activity of HBED Iron Chelator. Free Radical Biol. Med. 2001, 30, 170-177.
29. Denicola, A.; Souza, J. M.; Gatti, R. M.; Augusto, O.; Radi, R. Desferrioxamine Inhibition of the Hydroxyl Radical-Like Reactivity of Peroxynitrite: Role of the Hydroxamic Groups. Free Radical Biol. Med. 1995, 19, 11-19.
30. Bergeron, R. J.; Wiegand, J.; Weimar, W. R.; Nguyen, J. N.; Sninsky, C. A. Prevention of Acetic Acid-Induced Colitis by Desferrithiocin Analogs in a Rat Model. Dig. Dis. Sci. 2003, 48, 399-407.
31. Dean, R. T.; Nicholson, P. The Action of Nine Chelators on Iron-Dependent Radical Damage. Free Radical Res. 1994, 20, 83-101.
32. Grisham, M. B. Effect of 5-Aminosalicylic Acid on Ferrous Sulfate-Mediated Damage to Deoxyribose. Biochem. Pharmacol. 1990, 39, 2060-2063.
33. Grisham, M. B.; Ware, K.; Marshall, S.; Yamada, T.; Sandhu, I. Prooxidant Properties of 5-Aminosalicylic Acid. Possible Mechanism for Its Adverse Side Effects. Dig. Dis. Sci. 1992, 37, 1383-1389.
34. Cragg, L.; Hebbel, R. P.; Miller, W.; Solovey, A.; Selby, S.; Enright, H. The Iron Chelator L1 Potentiates Oxidative DNA Damage in Iron-Loaded Liver Cells. Blood 1998, 92, 632-638.
35. Brittenham, G. M. Iron Chelators and Iron Toxicity. Alcohol 2003, 30, 151-158.
36. Cooper, C. E.; Lynagh, G. R.; Hoyes, K. P.; Hider, R. C.; Cammack, R.; Porter, J. B. The Relationship of Intracellular Iron Chelation to the Inhibition and Regeneration of Human Ribonucleotide Reductase. J. Biol. Chem. 1996, 271, 20291-20299.
37. Davis, B. A.; Porter, J. B. Long-Term Outcome of Continuous 24-Hour Deferoxamine Infusion via Indwelling Intravenous Catheters in High-Risk β-Thalassemia. Blood 2000, 95, 1229-1236.
38. Davis, B. A.; Porter, J. B. Results of Long-Term Iron Chelation Treatment with Deferoxamine. Adv. Exp. Med. Biol. 2002, 509, 91-125.
39. Pippard, M. J. Desferrioxamine-Induced Iron Excretion in Humans. Bailliere's Clin. Haematol. 1989, 2, 323-343.
40. Naegeli, H.-U.; Zähner, H. Metabolites of Microorganisms. Part 193. Ferrithiocin. Helv. Chim. Acta 1980, 63, 1400-1406.
41. Hahn, F. E.; McMurry, T. J.; Hugi, A.; Raymond, K. N. Coordination Chemistry of Microbial Iron Transport. 42. Structural and Spectroscopic Characterization of Diastereomeric Cr(III) and Co(III) Complexes of Desferriferrithiocin. J. Am. Chem. Soc. 1990, 112, 1854-1860.
42. Anderegg, G.; Räber, M. Metal Complex Formation of a New Siderophore Desferrithiocin and of Three Related Ligands. J. Chem. Soc. Chem. Commun. 1990, 1194-1196.
43. Wolfe, L. C.; Nicolosi, R. J.; Renaud, M. M.; Finger, J.; Hegsted, M.; Peter, H.; Nathan, D. G. A Non-Human Primate Model for the Study of Oral Iron Chelators. Br. J. Haematol. 1989, 72, 456-461.
44. Bergeron, R. J.; Wiegand, J.; Dionis, J. B.; Egli-Karmakka, M.; Frei, J.; Huxley-Tencer, A.; Peter, H. H. Evaluation of Desferrithiocin and Its Synthetic Analogues as Orally Effective Iron Chelators. J. Med. Chem. 1991, 34, 2072-2078.
45. Bergeron, R. J.; Streiff, R. R.; Wiegand, J.; Vinson, J. R. T.; Luchetta, G.; Evans, K. M.; Peter, H.; Jenny, H.-B. A Comparative Evaluation of Iron Clearance Models. Ann. N. Y. Acad. Sci. 1990, 612, 378-393.
46. Bergeron, R. J.; Streiff, R. R.; Creary, E. A.; Daniels, R. D., Jr.; King, W.; Luchetta, G.; Wiegand, J.; Moerker, T.; Peter, H. H. A Comparative Study of the Iron-Clearing Properties of Desferrithiocin Analogues with Desferrioxamine B in a Cebus Monkey Model. Blood 1993, 81, 2166-2173.
47. Bergeron, R. J.; Wiegand, J.; McManis, J. S.; McCosar, B. H.; Weimar, W. R.; Brittenham, G. M.; Smith, R. E. Effects of C-4 Stereochemistry and C-4′ Hydroxylation on the Iron Clearing Efficiency and Toxicity of Desferrithiocin Analogues. J. Med. Chem. 1999, 42, 2432-2440.
48. Bergeron, R. J.; Wiegand, J.; Weimar, W. R.; Vinson, J. R. T.; Bussenius, J.; Yao, G. W.; McManis, J. S. Desazadesmethyldesferrithiocin Analogues as Orally Effective Iron Chelators. J. Med. Chem. 1999, 42, 95-108.
49. Bergeron, R. J.; Liu, C. Z.; McManis, J. S.; Xia, M. X. B.; Algee, S. E.; Wiegand, J. The Desferrithiocin Pharmacophore. J. Med. Chem. 1994, 37, 1411-1417.
50. Bergeron, R. J.; Wiegand, J.; Wollenweber, M.; McManis, J. S.; Algee, S. E.; Ratliff-Thompson, K. Synthesis and Biological Evaluation of Naphthyldesferrithiocin Iron Chelators. J. Med. Chem. 1996, 39, 1575-1581.
51. Bergeron, R. J.; Wiegand, J.; Weimar, W. R.; McManis, J. S.; Smith, R. E.; Abboud, K. A. Iron Chelation Promoted by Desazadesferrithiocin Analogues: An Enantioselective Barrier. Chirality 2003, 15, 593-599.
52. Bergeron, R. J.; Wiegand, J.; Ratliff-Thompson, K.; Weimar, W. R. The Origin of the Differences in (R)- and (S)-Desmethyldesferrithiocin: Iron-Clearing Properties. Ann. N. Y. Acad. Sci. 1998, 850, 202-216.
53. Bergeron, R. J.; Wiegand, J.; McManis, J. S.; Bussenius, J.; Smith, R. E.; Weimar, W. R. Methoxylation of Desazadesferrithiocin Analogues: Enhanced Iron Clearing Efficiency. J. Med. Chem. 2003, 46, 1470-1477.
54. Bergeron, R. J.; McManis, J. S.; Dionis, J. B.; Garlich, J. R. An Efficient Total Synthesis of Agrobactin and Its Gallium(III) Chelate. J. Org. Chem. 1985, 50, 2780-2782.
55. Bergeron, R. J.; Kline, S. J. Short Synthesis of Parabactin. J. Am. Chem. Soc. 1982, 104, 4489-4492.
56. Bergeron, R. J.; Garlich, J. R.; McManis, J. S. Total Synthesis of Vibriobactin. Tetrahedron 1985, 41, 507-510.
57. Radl, S.; Hezky, P.; Urbankova, J.; Vachal, P.; Krejci, I. Synthesis and Analgesic Activity of Some 1-Benzofurans, 1-Benzothiophenes and Indoles. Collection Czech. Chem. Commun. 2000, 65, 280-296.
58. Rahman, L. K. A.; Scrowston, R. M. 7-Substituted Benzo[b]-thiophenes and 1,2-Benzoisothiazoles. Part 1. Hydroxy- or-Methoxy-Derivatives. J. Chem. Soc., Perkin Trans. 1 1983, 2973-2977.
59. Bergeron, R. J.; Huang, G.; Weimar, W. R.; Smith, R. E.; Wiegand, J.; McManis, J. S. Desferrithiocin Analogue-Based Hexacoordinate Iron(III) Chelators. J. Med. Chem. 2003, 46, 16-24.
60. Grisham, M. B.; Granger, D. N. Neutrophil-Mediated Mucosal Injury. Role of Reactive Oxygen Metabolites. Dig. Dis. Sci. 1988, 33, 6S-15S.
61. Re, R.; Pellegrini, N.; Proteggente, A.; Pannala, A.; Yang, M.; Rice-Evans, C. Antioxidant Activity Applying an Improved ABTS Radical Cation Decolorization Assay. Free Radical Biol. Med. 1999, 26, 1231-1237.
62. 3H]Codeine. Drug Metab. Dispos. 1983, 11, 477-480.
63. Butz, R. F.; Jones, E. C.; Welch, R. M.; Findlay, J. W. A. Pharmacokinetics and O-Dealkylation of Morphine-3-alkyl Ethers in the Rat. A Radioimmunoassay Study. Drug Metab. Dispos. 1983, 11, 481-488.
64. Dayer, P.; Desmeules, J.; Leemann, T.; Striberni, R. Bioactivation of the Narcotic Drug Codeine in Human Liver Is Mediated by the Polymorphic Monooxygenase Catalyzing Debrisoquine 4-Hydroxylation (Cytochrome P-450 dbl/bufI). Biochem. Biophys. Res. Commun. 1988, 152, 411-416.
65. James, M. O.; Heard, C. S.; Hawkins, W. E. Effect of 3-Methylcholanthrene on Monooxygenase, Epoxide Hydrolase, and Glutathione S-Transferase Activities in Small Estuarine and Freshwater Fish. Aquat. Toxicol. 1988, 12, 1-15.
66. Gomori, G. Preparation of Buffers for Use in Enzyme Studies. Methods Enzymol. 1955, 1, 138-146.
67. Sangster, J. Octanol-Water Partition Coefficients: Fundamentals and Physical Chemistry; John Wiley and Sons: West Sussex, England, 1997.
68. Bergeron, R. J.; Streiff, R. R.; Wiegand, J.; Luchetta, G.; Creary, E. A.; Peter, H. H. A Comparison of the Iron-Clearing Properties of 1,2-Dimethyl-3-hydroxypyrid-4-one, 1,2-Diethyl-3-hydroxypyrid-4-one, and Deferoxamine. Blood 1992, 79, 1882-1890.
69. Wood, J. K.; Milner, P. F.; Pathak, U. N. The Metabolism of Iron-Dextran Given as a Total-Dose Infusion to Iron Deficient Jamaican Subjects. Br. J. Haematol. 1968, 14, 119-129.
70. Bergeron, R. J.; Wiegand, J.; Brittenham, G. M. HBED: A Potential Alternative to Deferoxamine for Iron-Chelating Therapy. Blood 1998, 91, 1446-1452.